Payment overview · 2025
General Payments
$263.33
13 reported records · 6 companies
Healthcare provider profile · identity verified
Dimitre Sirakov, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOWELL, MA · NPI 1932332681
Verified facts
What the public records show
CMS Open Payments records show Dimitre Sirakov, M.D. received $263.33 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 56.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $149.59 | 56.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.64 | 12.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.36 | 9.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.30 | 8.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.16 | 8.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.28 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.33 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $149.59 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.64 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 18 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 181 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
388 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 892 | 233 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 511 | 140 |
| Lisinopril | Lisinopril | 487 | 149 |
| Gabapentin | Gabapentin | 430 | 88 |
| Eliquis | Apixaban | 388 | 57 |
| Omeprazole | Omeprazole | 373 | 105 |
| Trazodone Hcl | Trazodone Hcl | 313 | 65 |
| Lorazepam | Lorazepam | 312 | 66 |
| Sertraline Hcl | Sertraline Hcl | 310 | 74 |
| Alprazolam | Alprazolam | 297 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 79 |
| Simvastatin | Simvastatin | 278 | 74 |
| Tramadol Hcl | Tramadol Hcl | 271 | 51 |
| Furosemide | Furosemide | 249 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 222 | 44 |
| Losartan Potassium | Losartan Potassium | 221 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 63 |
| Mirtazapine | Mirtazapine | 206 | 49 |
| Metformin Hcl | Metformin Hcl | 203 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 201 | 33 |
| Metformin Hcl Er | Metformin Hcl | 190 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 186 | 27 |
| Ozempic | Semaglutide | 181 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 45 |
| Allopurinol | Allopurinol | 165 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 54 |
| Clonazepam | Clonazepam | 158 | 20 |
| Atenolol | Atenolol | 147 | 37 |
| Famotidine | Famotidine | 140 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 119 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 28 |
| Alendronate Sodium | Alendronate Sodium | 117 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 41 |
| Donepezil Hcl | Donepezil Hcl | 101 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 23 |
| Finasteride | Finasteride | 92 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 26 |
| Spironolactone | Spironolactone | 85 | 22 |
| Bupropion Xl | Bupropion Hcl | 84 | 18 |
| Ibuprofen | Ibuprofen | 84 | 22 |
| Farxiga | Dapagliflozin Propanediol | 83 | 20 |
| Pregabalin | Pregabalin | 83 | 11 |
| Prednisone | Prednisone | 80 | 50 |
| Montelukast Sodium | Montelukast Sodium | 78 | 16 |
| Warfarin Sodium | Warfarin Sodium | 76 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 22 |
| Azithromycin | Azithromycin | 70 | 48 |
| Meloxicam | Meloxicam | 70 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 27 |
| Diazepam | Diazepam | 67 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 11 |
| Levetiracetam | Levetiracetam | 65 | 11 |
| Torsemide | Torsemide | 65 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Jardiance | Empagliflozin | 58 | 20 |
| Midodrine Hcl | Midodrine Hcl | 58 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 57 | 20 |
| Potassium Chloride | Potassium Chloride | 55 | 15 |
| Valsartan | Valsartan | 55 | 15 |
| Olanzapine | Olanzapine | 54 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 13 |
| Glipizide | Glipizide | 50 | suppressed |
| Cephalexin | Cephalexin | 49 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 35 |
| Glipizide Er | Glipizide | 49 | 17 |
| Lidocaine | Lidocaine | 48 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 25 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 42 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Labetalol Hcl | Labetalol Hcl | 37 | 12 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 12 |
| Lactulose | Lactulose | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Humalog | Insulin Lispro | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 23 | 15 |
| Naproxen | Naproxen | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Budesonide Ec | Budesonide | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.33 · 13 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, GEMTESA, Ozempic, PREVNAR 20, PROCLAIM, Rybelsus, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error